Laquinimod treatment in the R6/2 mouse model

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Huntington's disease (HD) is a neurodegenerative disorder with limited treatment options.
• The R6/2 transgenic mouse model mimics key HD deficits.
• Laquinimod, an immunomodulatory drug, is being developed for neurodegenerative diseases.

Purpose of the Study:

• To evaluate the therapeutic efficacy of laquinimod in the R6/2 mouse model of HD.
• To investigate laquinimod's neuroprotective effects and impact on disease pathology.
• To assess laquinimod's influence on metabolic activity and brain-derived neurotrophic factor (BDNF) levels.

Main Methods:

• Treatment of R6/2 mice with laquinimod.
• Assessment of motor function, survival, and weight.
• Histopathological analysis of neuronal preservation (NeuN, DARPP-32, ubiquitin) and marker expression (mhtt, iNOS).
• Biochemical analysis of BDNF levels in striatal and cortical neurons.
• Investigation of laquinimod's effects in an inducible PC12 cell-line model.

Main Results:

• Laquinimod did not affect weight or survival in R6/2 mice.
• Significant improvement in motor function was observed at 12 weeks.
• Preservation of neurons and reduction in mutant huntingtin (mhtt) and iNOS positive cells in the striatum and motor cortex.
• Increased BDNF levels in striatal neurons but not cortical neurons.
• No metabolic effects were observed in the PC12 cell-line model.

Conclusions:

• Laquinimod demonstrates a mild therapeutic effect on motor function and striatal histopathology in the R6/2 HD mouse model.
• The drug increases BDNF levels, suggesting a potential role in neuroprotection.
• Further research into BDNF-dependent pathways is warranted for HD treatment strategies.